CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-23). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1379 · Search date 2026-07-23 · Methodology v0.6

Intranasal NAD+ spray,
does it really help with Improved daily energy and focus and reduced fatigue through nasal absorption?

30-Second Summary
?
Evidence Grade ? · Safety unknown
No completed human intervention has tested an intranasal NAD+ finished product for daily energy, focus, or fatigue, so the grade is ? and the score is null.
What the
research shows
Intranasal NAD+ spray is rated ? because no completed human intervention result was found for energy, focus, or fatigue with this formulation. Studies of oral NR or NMN, intravenous NAD+, injections, or patches involve different exposure and cannot substitute. A 2026-registered combination study that includes intranasal NAD+ uses several interventions and has no posted efficacy results, so it does not establish finished-product efficacy. Absence of literature is not proof of ineffectiveness.
What the
ads claim
Sellers claim direct nose-to-brain delivery, instant cellular energy, and a focus boost, but human nasal absorption and clinical benefit have not been established. Oral-precursor trials and cellular metabolism explanations are not evidence for the nasal finished product.
*

Useful facts when choosing a product

  • NAD+ is a coenzyme in cellular redox and energy metabolism, but its essential endogenous role does not automatically establish benefit from exogenous nasal dosing.
  • Cross-border nasal sprays may be unapproved wellness products, with product-to-product variation in content, purity, sterility, preservatives, and delivered dose.
  • Human nasal safety data are inadequate to quantify burning, irritation, epistaxis, worsened rhinitis, contamination risk, or long-term harms.
Gap Measurement · Verdict 1379 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Human trials of oral NR and NMN have mainly assessed blood NAD+ metabolites and safety, with inconsistent clinical energy or cognitive benefits. No completed human result was found that jointly evaluated intranasal NAD+ absorption, pharmacokinetics, dose, nasal safety, and the claimed wellness outcomes. ClinicalTrials.gov entry NCT07475546 includes intranasal NAD+ 30 mg/day together with low-dose naltrexone, vitamin B12, metformin, and other interventions; no results were posted by the verification date.

02

Why this is classified as ?

There is no completed human intervention for the exact formulation-outcome pair. Under boundary rule ④, evidence from other routes or precursors is not extrapolated, giving ? with a null score.

Counterpoint. Persistent fatigue or poor concentration has many causes, including sleep disorders, anemia, thyroid disease, depression or anxiety, and medicines; evaluating the cause takes priority.

Rejudgment record. New verdict — There is no completed human intervention for the exact formulation-outcome pair. Under boundary rule ④, evidence from other routes or precursors is not extrapolated, giving ? with a null score.

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Improved daily energy?No completed human intervention result was found for an intranasal NAD+ finished product.
Improved focus?No result publication tested objective or subjective focus with this formulation.
Reduced fatigue?No human trial result evaluated fatigue reduction from intranasal NAD+ alone.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
ClinicalTrials.gov NCT07475546Registered multi-intervention exploratory studyTo be reportedComposite healthspan outcomes; not an isolated intranasal NAD+ effectIncludes intranasal NAD+ with multiple co-interventions and had no results by the verification date.Evidence-gap context rather than efficacy evidence
Covarrubias AJ et al. 2021Narrative review of NAD+ metabolism, aging, and clinical translationAcademic research supportNAD+ biology and clinical evidence for augmentation strategiesHuman evidence largely concerns oral precursors, while clinical benefits and tissue effects remain unresolved.Limits extrapolation from other formulations
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-23).

ClinicalTrials.gov. Combination Gerotherapeutic Interventions for Healthspan Improvement. NCT07475546. PMID: none. DOI: none.
checked
Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119-141. PMID: 33353981. PMCID: PMC7963035. DOI: 10.1038/s41580-020-00313-x.
checked
Damgaard MV, Treebak JT. What is really known about the effects of nicotinamide riboside supplementation in humans. Sci Adv. 2023;9(29):eadi4862. PMID: 37478182. PMCID: PMC10361580. DOI: 10.1126/sciadv.adi4862.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none

Cite this verdict

Intranasal NAD+ spray x Improved daily energy and focus and reduced fatigue through nasal absorption Evidence Grade ? card
[Chamgap] Intranasal NAD+ spray x Improved daily energy and focus and reduced fatigue through nasal absorption — Evidence Grade ?. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/energy/intranasal-nad-spray-energy-focus-fatigue/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.